Condition: Non Small Cell Lung Cancer · Pancreatic Ductal Adenocarcinoma · Sponsor: Phanes Therapeutics
This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in combination with a PD-1 inhibitor or chemotherapy.
This description comes directly from the study's public registry record.
Phanes Therapeutics · 858-766-0852 · clinical-trials@phanestx.com
Always discuss trial participation with your own doctor first.
| Carolina BioOncology Institute | Huntersville, North Carolina, United States | Recruiting |
| Sarah Cannon Research Institute University of Oklahoma | Oklahoma City, Oklahoma, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Tranquility Research | Webster, Texas, United States | Terminated |
| NEXT Oncology | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05431270